Division of Plastic Surgery, Department of Surgery, University of Washington, 325 9th Avenue, Box 359796, Seattle, WA, 98104, USA.
Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 E 98th St, New York, NY, 10029, USA.
Am J Clin Dermatol. 2020 Oct;21(5):627-639. doi: 10.1007/s40257-020-00558-4.
The coronavirus disease 2019 (COVID-19) pandemic has affected 18 million people and killed over 690,000 patients. Although this virus primarily causes respiratory symptoms, an increasing number of cutaneous manifestations associated with this disease have been reported.
The aim of this review was to collate and categorize the dermatologic findings reported in patients with COVID-19 and identify specific lesions that may facilitate diagnosis and prognostication.
An evidence-based review of the PubMed database was conducted on 14 May, 2020 using the search terms "Covid-19 skin," "Covid-19 rash," "Covid-19 exanthem," and "Covid-19 chilblains." Peer-reviewed publications containing original COVID-19 patient cases and a discussion of the associated cutaneous findings were included in the analysis.
The literature search identified 115 records, of which 34 publications describing 996 patients with dermatologic conditions were included. Case reports (n = 15), case series (n = 13), and observational prospective studies (n = 4) were the most common publication types. Acral lesions resembling pseudo-chilblains were the most frequent lesion identified (40.4% of cases), appearing in young adults (mean age, 23.2 years) after the onset of extracutaneous COVID-19 symptoms (55/100 patients). Erythematous maculopapular rashes affected 21.3% of patients, most frequently impacting middle-aged adults (mean age, 53.2 years) and occurring at the same time as non-cutaneous symptoms (110/187 patients). Vesicular rashes affected 13.0% of patients, appearing in middle-aged adults (mean age, 48.3 years) after the onset of other symptoms (52/84 patients). Urticarial rashes affected 10.9% of patients, appearing in adults (mean age, 38.3 years) and occurring at the same time as non-cutaneous symptoms (46/78 patients). Vascular rashes resembling livedo or purpura were uncommon (4% of cases), appearing in elderly patients (mean age, 77.5 years) and occurring at the same time as non-cutaneous COVID-19 symptoms (18/29 patients). Erythema multiforme-like eruptions, although infrequent (3.7% of cases), affected mostly children (mean age, 12.2 years).
Vesicular rashes may suggest an initial diagnosis of COVID-19, acral lesions may be most appropriate for epidemiological uses, and vascular rashes may be a useful prognostic marker for severe disease. As a potential correlate to disease severity, prognosis, or infectibility, it is critical that all healthcare professionals be well versed in these increasingly common cutaneous manifestations of COVID-19.
2019 年冠状病毒病(COVID-19)大流行已影响 1800 万人,并导致超过 69 万人死亡。尽管该病毒主要引起呼吸道症状,但越来越多的与该疾病相关的皮肤表现已被报道。
本综述的目的是整理和分类在 COVID-19 患者中报告的皮肤科发现,并确定可能有助于诊断和预后的特定病变。
于 2020 年 5 月 14 日在 PubMed 数据库中进行了基于证据的综述,使用的搜索词为“Covid-19 皮肤”、“Covid-19 皮疹”、“Covid-19 出疹”和“Covid-19 冻疮”。分析中包括了包含原始 COVID-19 患者病例并讨论相关皮肤发现的同行评审出版物。
文献检索共确定了 115 条记录,其中包括 34 篇描述了 996 例皮肤科疾病患者的出版物。病例报告(n=15)、病例系列(n=13)和观察性前瞻性研究(n=4)是最常见的出版物类型。类似于假性冻疮的肢端病变是最常见的病变(40.4%的病例),出现在年轻成人(平均年龄 23.2 岁)中,在出现皮肤外 COVID-19 症状后(55/100 例)。红斑性斑丘疹性皮疹影响 21.3%的患者,最常影响中年成人(平均年龄 53.2 岁),与非皮肤症状同时发生(187/110 例)。水疱性皮疹影响 13.0%的患者,出现在中年成人(平均年龄 48.3 岁)中,在其他症状出现后(52/84 例)。荨麻疹性皮疹影响 10.9%的患者,出现在成年患者(平均年龄 38.3 岁)中,与非皮肤症状同时发生(46/78 例)。类似于淤血性或紫癜性的血管性皮疹并不常见(4%的病例),出现在老年患者(平均年龄 77.5 岁)中,与非皮肤外 COVID-19 症状同时发生(29/18 例)。多形红斑样疹虽然不常见(3.7%的病例),但主要影响儿童(平均年龄 12.2 岁)。
水疱性皮疹可能提示 COVID-19 的初始诊断,肢端病变可能最适合流行病学用途,而血管性皮疹可能是严重疾病的有用预后标志物。由于它可能是疾病严重程度、预后或传染性的潜在相关因素,因此所有医疗保健专业人员都必须精通这些越来越常见的 COVID-19 皮肤表现。